Kim Min Hwan相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer

晚期胆道癌患者接受吉西他滨、顺铂和白蛋白紫杉醇治疗后疗效的分子决定因素

期刊:Clinical and Molecular Hepatology

影响因子:16.9

doi:10.3350/cmh.2025.1019

Kim, Daeseong; Sim, Nam Suk; Woo, Seonjeong; Kim, Min Hwan; Lee, Choong-Kun; Hong, Seung Soo; Kim, Sung Hyun; Hwang, Ho Kyoung; Kang, Chang Moo; Lee, Woo Jung; Jo, Jung Hyun; Chung, Taek; Hwang, Sohyun; Kang, Beodeul; Kim, Jung Sun; Kwon, Chang-Il; Kim, Sangwoo; Chon, Hong Jae; Kim, Chang Gon; Park, Young Nyun; Choi, Hye Jin

发表日期：2026

文献求助收藏

Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer

通过蛋白质基因组学解码三阴性乳腺癌患者的化疗耐药性

期刊:Genome Biology

影响因子:9.4

doi:10.1186/s13059-026-04053-7

Lee, Dong Ki; Kim, Min Hwan; Hwang, Yumi; Kim, Seul-Gi; Ryu, Won-Ji; Kim, Geon-Uk; Yun, Hyun Myoung; Park, Shinyoung; Lee, Jeong Dong; Han, Hyun Ju; Kim, Gun Min; Kim, Kyung-Hee; Park, Jong Bae; Kim, Min Jung; Koo, Ja Seung; Kim, Jee Ye; Park, Hyung Seok; Kim, Seung Il; Gee, Heon Yung; Park, Seho; Sohn, Joohyuk

发表日期：2026

文献求助收藏

Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer

骨骼肌放射密度低可预测晚期乳腺癌患者对 CDK4/6 抑制剂联合芳香化酶抑制剂的疗效

期刊:Journal of Cachexia Sarcopenia and Muscle

影响因子:9.1

doi:10.1002/jcsm.13666

Kim, Hyunwook; Baek, Seungjin; Han, Sookyeong; Kim, Gun Min; Sohn, Joohyuk; Rhee, Yumie; Hong, Namki; Kim, Min Hwan

发表日期：2025

文献求助收藏

Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15)

韩国 HR (+)、HER2 (-) 转移性乳腺癌患者使用帕博西尼治疗的全国真实世界实践模式和临床数据 (KCSG BR21-15)

影响因子:7.9

doi:10.1016/j.breast.2025.104500

Lee, Jieun; Lee, Dae-Won; Kim, Min Hwan; Kim, Jee Hung; Kim, Ju Won; Byun, Jae-Ho; Lee, Kyoung Eun; Kang, Myoung Joo; Koh, Su-Jin; Hong, Soojung; Won, Hye Sung; Kim, Han Jo; Park, In Hae; Shin, Seong Hoon; Baek, Sun Kyung; Kim, Seul-Gi; Koh, Sung Ae; Jung, Joo Young; Kim, Ji-Yeon; Kim, Gun Min; Shin, Kabsoo; Woo, In Sook; Kim, Hyun Seon; Im, Seock-Ah; Park, Yeon Hee

发表日期：2025

文献求助收藏

Artificial Intelligence-Powered Human Epidermal Growth Factor Receptor 2 Quantification and Clinical Outcomes in Human Epidermal Growth Factor Receptor 2-Positive Biliary Tract Cancer Treated With Trastuzumab Plus Folinic Acid, Fluorouracil, and Oxaliplatin

利用人工智能技术定量分析人表皮生长因子受体2阳性胆道癌患者接受曲妥珠单抗联合亚叶酸钙、氟尿嘧啶和奥沙利铂治疗后的临床结果

期刊:Jco Precision Oncology

影响因子:5.6

doi:10.1200/PO-25-00510

Kim, Hongsik; Oum, Chiyoon; Cho, Soo Ick; Jung, Wonkyung; Chon, Hong Jae; Lee, Myung Ah; Im, Hyeon-Su; Kim, Min Hwan; Nam, Taekjin; Ock, Chan-Young; Choi, Hye Jin; Lee, Choong-Kun

发表日期：2025

文献求助收藏

Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)

一项随机 II 期试验，旨在评估阿特珠单抗联合卡培他滨辅助治疗与卡培他滨单药治疗在接受新辅助化疗后仍有残留浸润性癌的三阴性乳腺癌中的疗效和安全性（MIRINAE 试验，KCSG-BR18-21）。

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-025-14673-0

Lee, Jieun; Ahn, Hee Kyung; Lee, Kyung-Hun; Jung, Kyung Hae; Park, Yeon Hee; Sim, Sung Hoon; Kim, Min Hwan; Kim, Jee Hyun; Kim, Jee Hung; Lee, Kyoung Eun; Park, Kyong Hwa; Bae, Jihong; Lee, Moon Hee; Lim, Seungtaek; Kim, Han Jo; Lee, Dae-Won; Jeong, Jae Ho; Kim, Ji-Yeon; Ahn, Jin Seok; Lee, Keun Seok; Sohn, Joohyuk; Suh, Koung Jin; Cha, Yoon Jin; Shin, Kabsoo; Kim, Sung-Bae; Chae, Heejung; Kim, Gun Min; Im, Seock-Ah; Park, In Hae

发表日期：2025

文献求助收藏

Overcoming BRAF and CDK4/6 inhibitor resistance by inhibiting MAP3K3-dependent protection against YAP lysosomal degradation

通过抑制MAP3K3依赖的YAP溶酶体降解保护作用，克服BRAF和CDK4/6抑制剂耐药性。

期刊:Experimental and Molecular Medicine

影响因子:12.9

doi:10.1038/s12276-024-01210-5

Park, Sanghyun; Ryu, Won-Ji; Kim, Tae Yeong; Hwang, Yumi; Han, Hyun Ju; Lee, Jeong Dong; Kim, Gun Min; Sohn, Joohyuk; Kim, Sang Kyum; Kim, Min Hwan; Kim, Joon

发表日期：2024

文献求助收藏

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

奥拉帕尼联合度伐利尤单抗（加或不加贝伐单抗）治疗既往未接受过PARP抑制剂治疗的铂敏感复发性卵巢癌：一项II期多队列研究

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-23-2249

Drew, Yvette; Kim, Jae-Weon; Penson, Richard T; O'Malley, David M; Parkinson, Christine; Roxburgh, Patricia; Plummer, Ruth; Im, Seock-Ah; Imbimbo, Martina; Ferguson, Michelle; Rosengarten, Ora; Steeghs, Neeltje; Kim, Min Hwan; Gal-Yam, Einav; Tsoref, Daliah; Kim, Jae-Hoon; You, Benoit; De Jonge, Maja; Lalisang, Roy; Gort, Eelke; Bastian, Sara; Meyer, Kassondra; Feeney, Laura; Baker, Nigel; Ah-See, Mei-Lin; Domchek, Susan M; Banerjee, Susana

发表日期：2024

文献求助收藏

Nanocrystal Formulation to Enhance Oral Absorption of Silybin: Preparation, In Vitro Evaluations, and Pharmacokinetic Evaluations in Rats and Healthy Human Subjects

纳米晶体制剂增强水飞蓟宾的口服吸收：制备、体外评价以及在大鼠和健康人体受试者中的药代动力学评价

期刊:Pharmaceutics

影响因子:5.5

doi:10.3390/pharmaceutics16081033

Seo, SeungRee; Kim, Gwan-Young; Kim, Min-Hwan; Lee, Kyung Won; Kim, Min-Jae; Chaudhary, Mansingh; Bikram, Khadka; Kim, Taeheon; Choi, Seungmok; Yang, Heejin; Park, Joo Won; Kim, Dae-Duk; Kim, Ki-Taek

发表日期：2024

文献求助收藏

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer

HER-2阴性转移性乳腺癌患者对艾立布林和纳武利尤单抗联合治疗反应相关的基因组和转录组特征

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s00262-024-03782-7

Park, Changhee; Suh, Koung Jin; Kim, Se Hyun; Lee, Kyung-Hun; Im, Seock-Ah; Kim, Min Hwan; Sohn, Joohyuk; Jeong, Jae Ho; Jung, Kyung Hae; Lee, Kyoung Eun; Park, Yeon Hee; Kim, Hee-Jun; Cho, Eun Kyung; Choi, In Sil; Noh, Seung-Jae; Shin, Inkyung; Cho, Dae-Yeon; Kim, Jee Hyun

发表日期：2024

文献求助收藏